Adaptive Biotechnologies (ADPT) Non-Current Debt (2022 - 2026)

Adaptive Biotechnologies has disclosed Non-Current Debt across 5 years of filings, most recently posting $124.7 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 5.17% year-over-year to $124.7 million; the TTM figure through Mar 2026 stood at $124.7 million (down 5.17% YoY), while the FY2025 annual figure was $126.6 million, down 4.42% from the prior year.
• Non-Current Debt came in at $124.7 million for Q1 2026 at Adaptive Biotechnologies, down from $126.6 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $132.7 million in Q3 2024 to a low of $124.7 million in Q1 2026.
• Average Non-Current Debt over 5 years is $129.5 million, with a median of $130.6 million recorded in 2023.
• Year-over-year, Non-Current Debt grew 4.71% in 2024 and decreased 5.17% in 2026.
• Over 5 years, Non-Current Debt stood at $125.4 million in 2022, then climbed by 4.23% to $130.7 million in 2023, then rose by 1.34% to $132.4 million in 2024, then fell by 4.42% to $126.6 million in 2025, then retreated by 1.44% to $124.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $124.7 million in Q1 2026, $126.6 million in Q4 2025, and $129.4 million in Q3 2025.